On April 13,2019 The company issued an interesting NR :
Veltex President and CEO Andreas Mauritzson commented, "We are very excited to welcome Dr. Haroutunian to our board who is the foremost expert in the field of addiction treatment and brings with him deep knowledge, extensive relationships and a unique approach to recovery. Dr. Haroutunian will be a cornerstone to Veltex's highly anticipated entry into the $25 billion health and wellness business. An important part of our business strategy, in part, will be to make targeted acquisitions of behavioral health facilities. Moreover, reduced capacity, the passage of mental health parity legislation and increased demand for mental health services, along with the current and future anticipated tax advantages to Veltex makes this extremely advantageous for our shareholders."
2 months later (08/05/19), The company issued another interesting NR:
Veltex Corporation announces the appointment of Luba Andrus, RPh., M.J. to the Board of Directors. Luba Andrus has more than 30 years of executive, operational, and retail leadership experience in both the pharmaceutical and cannabis industries, including owning co-founder and principal of two medical marijuana dispensaries in Illinois. Prior to entering the medical cannabis industry, she owned and operated numerous retail pharmacies which were ultimately sold to a Resurrection hospital system.
Rightfully, on that same day (post 17799), TheMikester reacted:
Got to hand it to them...they are putting one heck of a top team together.
Last month (April 2020): The Centers for Disease Control and Prevention estimates that the total "economic burden" of prescription opioid misuse alone in the United States is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction treatment, and criminal justice involvement.
At the same time, 'Finances online review for Business' published: The legalization of marijuana for recreational and medical purposes paved the way for its boom in the market.
During all that time, all we got is a deafening-silence from our publicly traded company.
Assuming we effectively some kind of a valuable asset on hand (???), wasn't is that ridicule, this could be close to morally criminal from a presumably competent management team, unable to profit from favourable circumstances (addition of presumably great people, growing cannabis markets, Opioid Overdose Crisis …) and totally negligent in their obligation to responsibly inform their shareholders.
Whatever will happen or not in the future, the behavior of our management will have been one of irresponsibility, … at least.